Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.568,47
    +114,69 (+0,34%)
     

  • Dow Jones

    41.393,78
    +297,01 (+0,72%)
     

  • Nasdaq

    17.683,98
    +114,30 (+0,65%)
     

  • Nikkei 225

    36.581,76
    -251,51 (-0,68%)
     

  • Petrolio

    69,24
    +0,27 (+0,39%)
     

  • Bitcoin EUR

    54.061,38
    +522,59 (+0,98%)
     

  • XRP EUR

    0,53
    +0,01 (+2,72%)
     

  • Oro

    2.606,20
    +25,60 (+0,99%)
     

  • EUR/USD

    1,1079
    +0,0002 (+0,02%)
     

  • S&P 500

    5.626,02
    +30,26 (+0,54%)
     

  • HANG SENG

    17.369,09
    +128,70 (+0,75%)
     

  • Euro Stoxx 50

    4.843,99
    +29,91 (+0,62%)
     

  • EUR/GBP

    0,8440
    +0,0003 (+0,04%)
     

  • EUR/CHF

    0,9395
    -0,0029 (-0,31%)
     

  • EUR/CAD

    1,5039
    +0,0003 (+0,02%)
     

Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

Terns Pharmaceuticals, Inc.
·1 minuto per la lettura
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.

FOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September.

2023 Wells Fargo Healthcare Conference
Location: Encore Boston Harbor, Boston, MA
Format: 1x1 Investor Meetings on Thursday, September 7

H.C. Wainwright 25th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York, NY
Format: Fireside Chat on Monday, September 11 at 11:30am ET

A live webcast of the Fireside Chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, NASH and obesity. Terns’ pipeline includes two clinical stage development programs including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/- an FXR agonist), and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Mark Vignola
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com